The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Roles of cMET/ErbB3 activation and overexpression in the development of resistance to EGFR inhibitors in NSCLC patients.
Myung-Ju Ahn
No relevant relationships to disclose
Silvia Park
No relevant relationships to disclose
Jong-Mu Sun
No relevant relationships to disclose
Jin Seok Ahn
No relevant relationships to disclose
Keunchil Park
No relevant relationships to disclose
Emma J. Langley
No relevant relationships to disclose
Phillip Sangwook Kim
No relevant relationships to disclose
Sharat Singh
No relevant relationships to disclose
Steve Lockton
No relevant relationships to disclose